Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

被引：0
|
作者：
Xenofon Baraliakos
Filip Van den Bosch
Pedro M. Machado
Lianne S. Gensler
Helena Marzo-Ortega
Bintu Sherif
Erhard Quebe-Fehling
Brian Porter
Corine Gaillez
Atul Deodhar
机构：
[1] Ruhr-University Bochum,Rheumazentrum Ruhrgebiet Herne
[2] Ghent University,Department of Internal Medicine and Pediatrics
[3] VIB Center for Inflammation Research,Department of Rheumatology
[4] University College London Hospitals NHS Foundation Trust,Department of Rheumatology, Northwick Park Hospital
[5] London North West University Healthcare NHS Trust,Centre for Rheumatology and Department of Neuromuscular Diseases
[6] University College London,Department of Medicine/Rheumatology
[7] University of California,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine
[8] San Francisco,undefined
[9] University of Leeds,undefined
[10] RTI Health Solutions,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharmaceuticals Corporation,undefined
[13] Oregon Health and Science University,undefined
来源：
Rheumatology and Therapy | 2021年 / 8卷
关键词：
Ankylosing spondylitis; Axial spondyloarthritis; Biologics; Interleukin-17; Low disease activity; Patient-reported outcomes; Remission; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：273 / 288
页数：15
相关论文
共 50 条
  • [1] Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
    Baraliakos, Xenofon
    Van den Bosch, Filip
    Machado, Pedro M.
    Gensler, Lianne S.
    Marzo-Ortega, Helena
    Sherif, Bintu
    Quebe-Fehling, Erhard
    Porter, Brian
    Gaillez, Corine
    Deodhar, Atul
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 273 - 288
  • [2] ASAS, BASDAI AND ASDAS REMISSION IN SECUKINUMAB TREATED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A POOLED ANALYSIS OF TWO PHASE 3 STUDIES
    Baraliakos, X.
    Van den Bosch, F.
    Machado, P.
    Gensler, L.
    Bintu, S.
    Porter, B.
    Gaillez, C.
    Deodhar, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 743 - 743
  • [3] SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES
    Deodhar, A.
    Baraliakos, X.
    Marzo-Ortega, H.
    Sieper, J.
    Gupta, A. D.
    Porter, B.
    Fox, T.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S107 - S107
  • [4] Reduction in fatigue in patients with active ankylosing spondylitis: results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Conaghan, P.
    Deodhar, A.
    Gossec, L.
    Ostergaard, M.
    Canete, J.
    Gandhi, K.
    Richards, H.
    Williams, N.
    Jugl, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 35 - 36
  • [5] REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF TWO PHASE 3 STUDIES OF SECUKINUMAB
    Kvien, T. K.
    Conaghan, P. G.
    Deodhar, A.
    Gossec, L.
    Ostergaard, M.
    Canete, J.
    Gandhi, K.
    Richards, H.
    Williams, N.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 823 - 823
  • [6] Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
    Deodhar, Atul A.
    Baeten, Dominique
    Sieper, Joachim
    Porter, Brian
    Widmer, Albert
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
    Kyburz, D.
    Deodhar, A.
    Baeten, D.
    Sieper, J.
    Porter, B.
    Widmer, A.
    Richards, H.
    SWISS MEDICAL WEEKLY, 2016, 146 : 6S - 6S
  • [8] Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials
    Deodhar, Atul A.
    Baraliakos, Xenofon
    Marzo-Ortega, Helena
    Sieper, Joachim
    Andersson, Mats
    Porter, Brian
    Fox, Todd
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 TRIALS
    Deodhar, A.
    Baraliakos, X.
    Marzo-Ortega, H.
    Sieper, J.
    Andersson, M.
    Porter, B.
    Fox, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 340 - 341
  • [10] SAFETY AND TOLERABILITY OF SECUKINUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED SAFETY ANALYSIS OF TWO INTERNATIONAL PHASE 3, RANDOMIZED, CONTROLLED TRIALS
    Deodhar, Atul
    Baeten, Dominique
    Sieper, Joachim
    Porter, Brian
    Richards, Hanno
    Widmer, Albert
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 139 - 140
12345